Burkitt Lymphoma | VJHemOnc

The Lymphoma Channel on VJHemOnc is supported by Janssen Pharmaceuticals (a Johnson & Johnson Company), Takeda, Karyopharm Therapeutics and MorphoSys. The supporters have no influence over the production of the content.

View Aggressive & Diffuse Large B-Cell Lymphoma Overview Page

Developing the novel Burkitt Lymphoma International Prognostic Index

Developing the novel Burkitt Lymphoma International Prognostic Index

Adam Olszewski • 8 Dec 2020

CNS invasion in B-cell lymphoma: a novel diagnostic and prognostic tool

CNS invasion in B-cell lymphoma: a novel diagnostic and prognostic tool

Adam Olszewski • 8 Dec 2020

IVAC +/- rituximab in R/R B-NHLs: a real-world data review

IVAC +/- rituximab in R/R B-NHLs: a real-world data review

David J. Straus • 2 Dec 2020

New technologies informing SOC in DLBCL

New technologies informing SOC in DLBCL

Christian Gisselbrecht • 14 Jun 2018

Describing clonal evolution in lymphoma

Describing clonal evolution in lymphoma

Michael Pfreundschuh et al. • 8 Sep 2017

Acute leukemia: epidemiology and progress in treatment

Acute leukemia: epidemiology and progress in treatment

Elias Jabbour • 4 Dec 2015

Panel discussion on the treatment of adolescent and young adult lymphoma patients

Panel discussion on the treatment of adolescent and young adult lymphoma patients

Catherine Bollard et al. • 23 Sep 2016